Response to Letter to the Editor: "Failure Rate of Antitumor Necrosis Factor Alpha Biologics in Very Early Onset Inflammatory Bowel Disease"

Inflamm Bowel Dis. 2024 Mar 1;30(3):513-514. doi: 10.1093/ibd/izad317.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Biological Products* / therapeutic use
  • Humans
  • Inflammatory Bowel Diseases* / drug therapy
  • Necrosis
  • Tumor Necrosis Factor-alpha

Substances

  • Biological Products
  • Tumor Necrosis Factor-alpha